Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Non-Current Liabilities (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $23.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 16.69% year-over-year to $23.2 million, compared with a TTM value of $23.2 million through Sep 2025, down 16.69%, and an annual FY2024 reading of $27.5 million, up 5.18% over the prior year.
  • Total Non-Current Liabilities was $23.2 million for Q3 2025 at Barinthus Biotherapeutics, down from $24.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $32.6 million in Q3 2023 and bottomed at $23.2 million in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $27.4 million, with a median of $26.5 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities dropped 18.48% in 2023, then grew 7.8% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $25.8 million in 2021, then dropped by 1.9% to $25.3 million in 2022, then rose by 3.53% to $26.2 million in 2023, then grew by 5.18% to $27.5 million in 2024, then fell by 15.84% to $23.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BRNS at $23.2 million in Q3 2025, $24.5 million in Q2 2025, and $25.0 million in Q1 2025.